US pharma companies got more FDA warning than Indian companies


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ FDA Logo
US companies get more US FDA warnings than Indian companies.

The Indian pharma industry, which is knocked repeatedly for poor manufacturing practices across the planet, seems to have pulled its strings relatively. American drug firms got 54 warning letters by the USFDA, while India on its heels with 17 such notices within the year ended September (US financial year). China tailing with 14 warnings.

A company smacked with a warning letter is stopped from introducing new products within the US, restricting its ability to extend sales within the world’s top pharmaceutical market. Earlier, reportedly emerging economies like India or China topped the list.
Data integrity issues that include inappropriate manufacturing practices and lascivious in testing medicines, still corrode the industry with 32 of 98 warning letters in 2019. within the previous year, 34 of 94 warning letters were thanks to data integrity lapses, which have a big impact on drug product quality.
Several pharma companies were hauled up by the US regulator over issues like careless documentation, neglecting test results and unhygienic manufacturing facilities with open toilet drains. Indian companies command almost 35% share within the highly lucrative US generic market, valued at closely $70 billion.
In 2019, major companies including Lupin, Aurobindo, Glenmark and Emcure Pharma were issued warning letters for significant violations of current good manufacturing practise regulations. Typically, the action follows inspections by the US regulator.US

Tags : #usfda #morewarnings #uscompanies #medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Smart Operating Rooms: The Future of Hospital OTNovember 21, 2026
Smartphone Diagnostics: Phones as Medical Screening ToolsNovember 21, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026